Health Product Shortages homepage
Welcome to Health Product Shortages Canada, the website for mandatory reporting of health product shortages and discontinuations by regulated parties. Anyone can search the database of shortage and discontinuation reports. More information can be found on the About & Resources Page.
Early reporting of shortages and discontinuations provides Health Canada, provincial/territorial governments, supply chain stakeholders, and health professionals details needed to help them monitor and manage supply. Shortages can be caused by many factors. Some last longer and are more complex than others. Because companies have to report every time they cannot fully meet demand, not all of the reports on this site are cause for concern at the patient level. Most are successfully managed before they impact patients.
The shortage database has a flag that indicates ones that are Tier 3 drug shortages, which are those that could potentially have the highest impact on Canada's drug supply and health care system. A Tier 3 designation is decided by the Tier Assignment Committee (TAC), composed of federal and provincial/territorial governments, healthcare professionals, and industry stakeholders.
Ensuring people can get the health products they need is a top priority for Health Canada. Health Canada works closely with many partners to prevent shortages, mitigate their impacts, and help resolve them when they occur.
If you would like to know more about shortages like why they happen, how long they last, the actions being taken to reduce impacts on Canadians, and actions you can take if a drug you use is in shortage, please consult the information on Canada.ca (open in new tab).
Below are the newest shortage and discontinuation reports and updates to existing ones.
LEGEND
!!T3 denotes an actual Tier 3 shortage/discontinuation
!T3 denotes an anticipated Tier 3 shortage/discontinuation
Shortage Reports
| Brand name | Company Name | Status | Strength | Update | Date Updated | View Report |
|---|---|---|---|---|---|---|
| (20MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP | BAXTER CORPORATION | Actual shortage | 450MG 5G 150MG | Updated Report | 2026-02-28 | 278883 |
| MYLAN-PANTOPRAZOLE T | MYLAN PHARMACEUTICALS ULC | Actual shortage | 40MG | Updated Report | 2026-02-24 | 275166 |
| MYLAN-VERAPAMIL SR | MYLAN PHARMACEUTICALS ULC | Anticipated shortage | 120MG | New Report | 2026-02-24 | 278878 |
| MYLAN-RIVASTIGMINE PATCH 5 | MYLAN PHARMACEUTICALS ULC | Anticipated shortage | 4.6MG | New Report | 2026-02-24 | 278875 |
| MYLAN-NAPROXEN/ESOMEPRAZOLE MR | MYLAN PHARMACEUTICALS ULC | Anticipated shortage | 20MG 500MG | New Report | 2026-02-24 | 278872 |
| MYLAN-LANSOPRAZOLE | MYLAN PHARMACEUTICALS ULC | Anticipated shortage | 15MG | New Report | 2026-02-24 | 278869 |
| MYLAN-INDAPAMIDE | MYLAN PHARMACEUTICALS ULC | Anticipated shortage | 1.25MG | New Report | 2026-02-24 | 278866 |
| CLARUS | MYLAN PHARMACEUTICALS ULC | Anticipated shortage | 40MG | New Report | 2026-02-24 | 278863 |
| MYLAN-RIZATRIPTAN ODT | MYLAN PHARMACEUTICALS ULC | Actual shortage | 10MG | Updated Report | 2026-02-24 | 276592 |
| MYLAN-LAMOTRIGINE | MYLAN PHARMACEUTICALS ULC | Actual shortage | 150MG | Updated Report | 2026-02-24 | 278278 |
Discontinuation Reports
| Brand name | Company Name | Status | Strength | Update | Date Updated | View Report |
|---|---|---|---|---|---|---|
| 20% PROSOL | BAXTER CORPORATION | To be discontinued | 1.34G 1.35G 0.98G 0.32G 0.76G 0.6G 1.02G 1G 2.06G 1.08G 1.44G 2.76G 1.08G 1.02G 1.96G 0.05G 1.18G | New Report | 2026-02-27 | 278886 |
| SANDOZ MONTELUKAST | SANDOZ CANADA INCORPORATED | Discontinued | 4MG | New Report | 2026-02-23 | 278699 |
| SANTYL | SMITH & NEPHEW INC | Discontinued | 250UNIT | New Report | 2026-02-23 | 278673 |
| !T3 PROCYTOX | BAXTER CORPORATION | To be discontinued | 200MG | New Report | 2026-02-23 | 265253 |
| EBIXA | LUNDBECK CANADA INC | To be discontinued | 10MG | New Report | 2026-02-20 | 278530 |

